Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iNovacia, a Swedish provider of drug discovery solutions has developed inhibitors of a target protein in the parasite Schistosoma.
Subscribe to our email newsletter
The company is a part of the EU-funded project SEtTReND (Schistosoma Epigenetics – Targets, Regulation, New Drugs) with major focus on drug discovery, dddmag.com reported.
The project involves making new active compounds against the parasitic disease, schistosomiasis.
iNovacia’s inhibitors against the parasitic target protein will be tested directly against the parasites in the next step.